Navidea Biopharmaceuticals, Inc (NAVB,NEOP) Wednesday said it has started to enroll subjects in its Phase 2b imaging study of NAV4694 for detection of cerebral ß-amyloid plaque in subjects diagnosed with Mild Cognitive Impairment or MCI. The first patient has been enrolled by the Alzheimer's Disease Center at Quincy Medical Center in Quincy, MA, added the company.
Navidea said the purpose of the study is to determine whether NAV4694 positron emission tomography scan findings have the ability to distinguish subjects with MCI who progress to Alzheimer's disease from those who do not.
Commenting on the development, Anil Nair, chief of Neurology and Head of the Alzheimer's Disease Center at Quincy Medical Center in Quincy, MA said, "Clinical trial results to date indicate that NAV4694 shows favorable sensitivity and specificity in detecting ß-amyloid while exhibiting low white-matter uptake for clearer images that may assist in differential diagnoses associated with MCI. If AD could be diagnosed at an earlier stage, before clinical dementia has fully developed, the potential for successful intervention with current and future treatments could be improved considerably."
For comments and feedback: editorial@rttnews.com